Ken Griffin Biodesix Inc Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.21 - $1.71 $13,915 - $19,665
11,500 New
11,500 $17,000
Q4 2023

Feb 14, 2024
SELL
$1.2 - $2.13 $360 - $639
-300 Reduced 33.33%
600 $1,000
Q3 2023

Nov 14, 2023
BUY
$1.04 - $1.74 $936 - $1,566
900 New
900 $1,000
Q4 2022

Feb 14, 2023
SELL
$0.98 - $2.3 $39,298 - $92,230
-40,100 Reduced 92.18%
3,400 $7,000
Q3 2022

Nov 14, 2022
SELL
$1.24 - $2.89 $992 - $2,312
-800 Reduced 1.81%
43,500 $55,000

Others Institutions Holding BDSX

# of Institutions
50
Shares Held
52.5M
Call Options Held
500
Put Options Held
11.5K
View Full List

About BIODESIX INC

BDSX Quotes by TradingView
  • Ticker BDSX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 39,982,000
  • Market Cap $56.4M
  • Description
  • Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...
More about BDSX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email